It is because hemp only recently became legal to grow in the U.S. that many of the finished hemp goods that you see for sale in America, from food products to clothing to building materials, are part of an imported hemp industry that has surpassed $688 million annually. The size of this import industry was one of the major catalysts for hemp legalization in the U.S. As a renewable source of a range of products, hemp provides an exciting new step in American agriculture.
The studies on CBD for headache pain are still in their infancy, but with promising results so far. A 2017 study published in the Cannabis and Cannabinoid Research Journal worked with 26 people who were experiencing rebound headaches. The pain management results were better for the cannabis-nabilone formula over either ibuprofen or nabilone alone. (As a nerdy side note, the article is a great read if you’re interested in the history of cannabis as a pain reliever.)
Generalized pain, for instance, has dozens upon dozens of high profile research and clinical studies that have been carried out in universities and laboratories around the globe. One of the most well-publicized of these studies took place back in 2008, in which results determined that “cannabinoid analgesics (pain relievers) have generally been well tolerated in clinical trials … with acceptable adverse event profiles (meaning acceptable effectiveness for practical use).
Truth be told, one of the biggest draws to using CBD oil for pain has been the fact that it has little distinguishable side-effects or contraindications with other medications. In fact, in a massive report that was published by the World Health Organization during last year’s 2017 Expert Committee on Drug Dependence, it was (finally) declared to the world that CBD is a “safe, well tolerated [compound, which] is not associated with any significant adverse public health effects.”